Your search for baricitinib returned 13 results

Compared with dual therapy, significant survival benefit seen with dexamethasone, remdesivir, and baricitinib but no change in length of stay

Abrocitinib, 200 mg daily, and upadacitinib, 30 mg daily, slightly better than dupilumab, while upadacitinib, 15 mg daily is similar to dupilumab

Reduction in death seen at 28, 60 days for patients receiving invasive mechanical ventilation, extracorporeal membrane oxygenation

JAK inhibitor baricitinib strongly recommended for the treatment of severe or critical COVID-19

The applications are supported by data from two 2two phase 3 induction studies and one 1 maintenance study.

But placebo-controlled trial shows lower all-cause mortality at 28 days and 60 days in patients receiving baricitinib plus standard of care

The revisions are based on a completed review of a large randomized safety clinical trial, which included 4362 patients with rheumatoid arthritis.

Long-term sustained outcomes seen among adults with moderate-to-severe atopic dermatitis

Results from 2 studies show statistically significant improvement in scalp hair regrowth with baricitinib, a JAK inhibitor.

Findings showed that the trial did not meet statistical significance on the primary endpoint.